Warner Chilcott Considers Repricing Counter

26 Jan 2010

Warner Chilcott wasn’t able to secure approval for the proposed repricing on its $2.1 billion term loan to finance its acquisition of Procter & Gamble’s prescription drug unit.

--Katherine Greene

Warner Chilcott wasn’t able to secure approval for the proposed repricing on its $2.1 billion term loan to finance its acquisition of Procter & Gamble’s prescription drug unit. The repricing was launched a week ago and lenders were given until today to make a decision. ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial